74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Lifecore Biomedical Inc
Closed
Sector Consumer defensive
5.61 -2.77
Overview
Share price change
24h
Min
5.59
Max
5.67
Income | -1K -6.6M |
|---|---|
Sales | -5.3M 33M |
P/E Sector Avg | 201.137 44.075 |
EPS | -0.253 |
Profit margin | -20.179 |
Employees | 524 |
EBITDA | -5.5M |
Next Earnings | 7 May 2025 |
|---|
Market Cap | 21M 209M |
|---|---|
Previous open | 8.38 |
Previous close | 5.61 |
News Sentiment
By Acuity
50%
50%
62 / 154 Consumer defensive
Lifecore Biomedical Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Lifecore Biomedical Inc Forecast
Sentiment
By Acuity
62 / 154 Consumer defensive
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Lifecore Biomedical Inc
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
